Abstract:BackgroundWith an estimated 249 million cases and 608,000 deaths in 2022 malaria continues to cause substantial morbidity and mortality worldwide, mostly in children in Sub-Saharan Africa due to Plasmodium falciparum . Circumsporozoite protein (CSP) coats the surface of the P. falciparum sporozoite and is the target of the two vaccines approved by the World Health Organization (WHO). CSP has three major regions: the N-terminus, the central repeat region, and the C-terminus, which contains highly variable T cell epitopes; only a fragment of the central repeat region and the C-terminus are represented by the two approved vaccines. The junction between the N-terminal Region 1 and the NANP repeat region ("junctional region") is not represented in the approved vaccines and was recently found to be a target of protective antibody responses.MethodsWe used a repetitive controlled human malaria infection (rCHMI) model in which eight malaria-naïve participants were infected with P. falciparum up to three times over two years to identify immune responses associated with acquisition of natural immunity. We evaluated samples from the day of each CHMI and 18 days after each CHMI. We measured antibody responses using a peptide microarray inclusive of hundreds of P. falciparum proteins and focused our current study on the response to CSP. The amino acid sequences of CSP from the NF54 strain and 4 additional CSP variants were represented as 16-amino acid peptides with 13-amino acid overlap. Signal intensities at each amino acid position were estimated using a sliding window approach that averaged signals from adjacent overlapping peptides. Participants who comprised a "delayed parasitemia group" (n = 5) had onset of PCR-confirmed parasitemia 13 or more days after the last CHMI, a sign of developing humoral immunity. A "non-delayed parasitemia group" (n = 3) was comprised of those had onset of parasitemia within 12 or fewer days after the last CHMI. Along each amino acid position, the median signal intensities for all CSP variants are presented to describe the participants' antibody responses at each time point. Wilcoxon signed rank test was used to compare medians between timepoints; p-values < 0.05 without adjustment for multiple comparisons were considered statistically significant.ResultsAfter three rCHMIs, participants developed antibody responses to amino acids corresponding to the junctional region and the central repeat region (P<0.05). When participants are grouped by time to parasitemia, those who showed delayed parasitemia development had strong immune responses to the junctional region while the non-delayed group did not. Antibody responses to the C-terminal region were more variable among the 5 CSP variant sequences compared to other regions.ConclusionOur results showed higher junctional region antibody response in participants with delayed time to parasitemia. We also demonstrate variable antibody response to the C-terminal region, a region with known greater genetic variability that has been previously associated with allele-specific vaccine escape and concern for decreased efficacy of current WHO-approved vaccines. Taken together, our results support future vaccine development that focuses on the conserved junctional region over the polymorphic C-terminal region.

Antibodies to PfEMP1 and Variant Surface Antigens: Protection after Controlled Human Malaria Infection in Semi-immune Kenyan Adults

Longitudinal Analysis of Naturally Acquired PfEMP1 CIDR Domain Variant Antibodies Identifies Associations with Malaria Protection.

Autoantibodies Inhibit Plasmodium Falciparum Growth and Are Associated with Protection from Clinical Malaria

Functional Human IgA Targets a Conserved Site on Malaria Sporozoites

Plasmodium Falciparum-Specific IgM B Cells Dominate in Children, Expand with Malaria and Produce Parasite Inhibitory IgM

Naturally Acquired Antibodies Specific for Plasmodium Falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection from Malaria.

Dendritic Cell Responses to Plasmodium Falciparum in a Malaria-Endemic Setting

Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.

Safety and Efficacy of a Monoclonal Antibody Against Malaria in Mali.

Antibodies to specific domains of Plasmodium falciparum erythrocyte membrane protein-1 and its relationship with protection from severe malarial anemia: A prospective study among Ghanaian children

The Progression of Epitope-specific Antibody Responses toPlasmodium falciparum Circumsporozoite Protein Following Consecutive Malaria Infections in Naïve Adults: A Repetitive Controlled Human Malaria Infection Study

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria

Antibody Targets on the Surface of Plasmodium falciparum–Infected Erythrocytes That Are Associated With Immunity to Severe Malaria in Young Children

Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection

A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children

IgM plays a prominent role in naturally acquired immunity against Plasmodium falciparum gametocytes

A Molecular Analysis of Memory B Cell and Antibody Responses Against Plasmodium falciparum Merozoite Surface Protein 1 in Children and Adults From Uganda

Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans